• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Illidge, Timothy M
    Chan, Clara
    Affiliation
    School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.uk
    Issue Date
    2008-07
    
    Metadata
    Show full item record
    Abstract
    The outcome for patients with follicular lymphoma (FL) has substantially improved over the last few years. This improved survival appears to be largely related to the increasingly widespread use of anti-CD20 monoclonal antibody (mAb) rituximab in the therapy of FL today, either in combination with chemotherapy, for remission 'induction' and more recently as 'maintenance' therapy. Encouraging results have also been reported from radiolabelled anti-CD20 mAb or radioimmunotherapy (RIT), which exploits the unique method of action of this approach and high radiosensitivity of FL. High response rates and durable remissions have been seen with both (90)Y Ibritumomab tiuxetan and (131)I Tositumomab, and more recently compelling data are emerging demonstrating the efficacy of using these drugs as consolidation after initial treatment with chemotherapy or rituximab plus chemotherapy combinations. This review will focus on the current approaches and explore the data that has led to the emergence of a new nomenclature appearing in the language of clinicians involved in the treatment of FL, namely 'induction' therapy, 'consolidation' of initial response and 'maintenance' therapy. The current treatment approaches that have led to such increased optimism regarding the therapeutic outcome in FL are evaluated and discussed.
    Citation
    How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? 2008, 49 (7):1263-73 Leuk. Lymphoma
    Journal
    Leukemia & Lymphoma
    URI
    http://hdl.handle.net/10541/68741
    DOI
    10.1080/10428190802090805
    PubMed ID
    18604715
    Type
    Article
    Language
    en
    ISSN
    1029-2403
    ae974a485f413a2113503eed53cd6c53
    10.1080/10428190802090805
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research
    Clinical Oncology
    School of Cancer and Imaging Sciences

    entitlement

    Related articles

    • Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
    • Authors: Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A
    • Issue date: 2008 Nov 10
    • Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
    • Authors: Seiler T, Hiddemann W, Dreyling M
    • Issue date: 2009 Nov
    • Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
    • Authors: Cicone F, Russo E, Carpaneto A, Prior JO, Delaloye AB, Scopinaro F, Ketterer N
    • Issue date: 2011 Sep
    • [Therapy of follicular lymphoma].
    • Authors: Buske C, Unterhalt M, Hiddeman W
    • Issue date: 2007 Apr
    • Radioimmunotherapy in follicular lymphoma.
    • Authors: Illidge T, Morschhauser F
    • Issue date: 2011 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.